Data compiled by Redley Lamar · ChainSifter Intelligence
0Suppliers
10Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
Enliven Therapeutics, Inc. (ELVN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
13Total relationships
1Distinct source URLs
3High confidence
0.731Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Enliven Therapeutics, Inc. Suppliers
No suppliers on recordEnliven Therapeutics, Inc. has not yet been matched to upstream suppliers in our database, or is still being processed.
Reciprocal relationship from MYGN graph: Reciprocal relationship from ELVN graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from ELVN graph: nce to cover us for costs and expen…
nce to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential …
at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness. There are currently six BCR-ABL TKIs approved for use in CML by the FDA: No…
Reciprocal relationship from NVSEF graph: Reciprocal relationship from ELVN graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from ELVN graph: Reciprocal relationship from NVSE…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from ELVN graph: nce to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazar…
SNYNF
Sanofi
72%
nce to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential …
CRESTVIEW-LLC
CRESTVIEW-LLC
62%
, marketing, medical and distribution infrastructure to commercialize any approved product candidates; • contract to manufacture any clinical product candidates or approved product candidates; for ex…
DELAWARE-GENERAL-CORPORATION
DELAWARE-GENERAL-CORPORATION
62%
financial condition. We will need substantial additional funding before we can complete the development of our product candidates. If we are unable to obtain such additional capital on favorable term…
IGUANA-MERGER-SUB-INC
IGUANA-MERGER-SUB-INC
62%
tries in Europe, which may increase the cost of manufacturing our product candidates; • contract for supplies and drug product for use in potential combination studies or in comparator arms of clinic…
LIQUIDITY-BUSINESS-ENLIVEN-INC
LIQUIDITY-BUSINESS-ENLIVEN-INC
62%
ts and liabilities: Prepaid expenses, other current and long-term assets 1,647 ( 152 ) Operating lease liabilities ( 97 ) ( 69 ) Accounts payable ( 519 ) 220 Accrued expenses and other liabilities ( …
Enliven Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ELVN-DEBT-9276
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2023-12-31.
ELVN-DEBT
Debt stack $302,000
90%
Market cache reports total debt of $302,000.
Enliven Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Enliven Therapeutics, Inc..
Enliven Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
ELVN-OWNER-ORBIMED-ADVISORS-LLC
ORBIMED ADVISORS LLC
90%
13F overlay lists ORBIMED ADVISORS LLC as top holder; 175 tracked holders.
Enliven Therapeutics, Inc. Extended Supply Chain Network
